UDC: 615.03
BBC: 52.81
Georgieva K.S., Pavlova S.I., Bogdanova S.M.
Pharmacokinetic and Pharmacodynamic Features of the Response to Warfarin thErapy on the Example of Excessive Hypocoagulation Development in a Patient of the Chuvash Population with a Prosthetic Heart Valve
Keywords: pharmacogenetics, Warfarin, international normalized ratio, prosthetic heart valve, atrial fibrillation, Chuvash population, CYP2C9, VKORC1, ethnic group
Atrial fibrillation remains a significant public health problem worldwide to this day, and in combination with valvular heart disease it worsens the patient's prognosis. in patients with prosthetic heart valves, the use of anticoagulants is a prerequisite to prevent thromboembolic complications. Indirect anticoagulants, in particular, Warfarin, remain the front-line therapy. This article presents a clinical case of hypersensitivity to Warfarin in a patient of the Chuvash population with an implanted mitral valve. in the postoperative period, difficulties were identified to control the target international normalized ratio. the article examines the factors that could contribute to an increase in sensitivity to Warfarin in this patient. Current literature data on polymorphisms of the CYP2C9 and VKORC1 genes that predetermine hypersensitivity to Warfarin and their prevalence are presented. the clinical case demonstrates the prospects for introducing pharmacogenetic testing as a tool that increases the effectiveness and safety of pharmacotherapy in certain ethnic groups.
References
- Sychev D.A., Antonov I.M., Ignat’ev I.V. et al Antikoagulyantnoe deistvie i bez-opasnost’ primeneniya varfarina pri ego dozirovanii, osnovannom na rezul’tatakh farmakogeneticheskogo testirovaniya: rezul’taty pervogo rossiiskogo prospektivnogo issledovaniya [Anticoagulant effect and safety of warfarin in its dosing based on the results of pharmacogenetic testing: results of the first Russian prospective study]. Kardiologiya, 2010, no. 5. pp. 42–46.
- Bairova T.A., Sambyalova A.Yu., Rychkova L.V. et al. Farmakogeneticheskii algoritm dozirovaniya varfarina v rossiiskoi populyatsii [Pharmacogenetic algorithm of warfarin dosing in the Russian population]. Acta biomedica scientifica, 2019, no. 4(3). pp. 40–44.
- Georgieva K.S., Pavlova S.I., Bogdanova S.M. et al. Klinicheskii sluchai personalizatsii terapii varfarinom: farmakogeneticheskoe te-stirovanie i mezhlekarstvennoe vzaimodeistvie [Clinical case of personalization of warfarin therapy: pharmacogenetic testing and drug-drug interaction]. Farmakogenetika i farmakogenomika, 2020, 2, pp. 30–31.
- Mirzaev K.B., Fedorinov D.S., Ivashchenko D.V., Sychev D.A. Mul’tietnicheskii analiz kardiologicheskikh farmakogeneticheskikh markerov genov tsitokhroma R450 i membrannykh transporterov v rossiiskoi populyatsii [Multiethnic analysis of cardiological pharmacogenetic markers of cytochrome P450 genes and membrane transporters in the Russian population]. Ratsional’naya Farmakoterapiya v kardiologii, 2019, no. 15(3), pp. 393–406.
- Rumyantsev N.A., Sychev D.A., Kukes V.G. et al. Opyt individualizatsii primeneniya i dozirovaniya peroral’nykh antikoagulyantov v usloviyakh funktsionirovaniya tsentra personalizirovannoi meditsiny [Experience of individualization of the use and dosing of oral anticoagulants in the functioning of the center for personalized medicine]. Kazanskii meditsinskii zhurnal, 2015, 96(6), pp. 1065–1068.
- Skirdenko Yu.P., Nikolaev N.A. Novye podkhody k individualizirovannomu vyboru peroral’nykh antikoagulyantov u bol’nykh fibrillyatsiei predserdii [New approaches to the individualized choice of oral anticoagulants in patients with atrial fibrillation]. Ratsional’naya farmakoterapiya v kardiologii, 2018, no. 14(1), pp. 58–64.
- Sychev D.A., Shuev G.N., Torbenkov E.S., Adriyanova M.A. Personalizirovannaya me-ditsina: vzglyad klinicheskogo farmakologa [Personalized medicine: the view of a clinical pharmacologist]. Consilium Medicum, 2017, no. 19(1), 61–68.
- Caldeira D., David C., Costa J. et al. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother., 2018, no. 4(2), pp. 111–118.
- Lip Gyh, Andreotti F., Fauchier L., Huber K. et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011, 13(5), pp. 723–746.
- Lip Gyh, Collet J.P., Caterina R., Fauchier L. et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace, 2017, 19(11), pp. 1757–1758.
- Malik A.H., Yandrapalli S., Aronow W.S., Panza J.A., Cooper H.A. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. Heart., 2019, 105(18), pp. 1432–1436.
- Poli D., Antonucci E., Grifoni E., Abbate R. et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol., 2009, 54(11), pp. 999–1002.
- Poli D., Antonucci E., Marcucci R., Fatini C. et al. Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. Thromb Res., 2007, 121(3), pp. 347–352.
About authors
- Georgieva Ksenia S.
- Assistant Lecturer, Department of Pharmacology, Clinical Pharmacology and Biochemistry , Chuvash State University, Russia, Cheboksary (KseniaPharm@yandex.ru; ORCID: https://orcid.org/0000-0002-8632-1408)
- Pavlova Svetlana I.
- Doctor of Medical Sciences, Associate Professor, Head of the Department of Pharmacology, Clinical Pharmacology and Biochemistry, Chuvash State University, Russia, Cheboksary (flavonoid@yandex.ru; ORCID: https://orcid.org/0000-0001-9976-7866)
- Bogdanova Svetlana M.
- Candidate of Medical Sciences, Associate Professor, Department of Pharmacology, Clinical Pharmacology and Biochemistry, Chuvash State University, Russia, Cheboksary (svetochbogd@mail.ru; ORCID: https://orcid.org/0000-0002-0728-9092)
Article link
Georgieva K.S., Pavlova S.I., Bogdanova S.M. Pharmacokinetic and Pharmacodynamic Features of the Response to Warfarin thErapy on the Example of Excessive Hypocoagulation Development in a Patient of the Chuvash Population with a Prosthetic Heart Valve [Electronic resource] // Acta medica Eurasica. – 2022. – №4. P. 97-102. – URL: https://acta-medica-eurasica.ru/en/single/2022/4/11/. DOI: 10.47026/2413-4864-2022-4-97-102.